Form 4: Tenaya Therapeutics CEO Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


Tenaya Therapeutics CEO Faraz Ali sold shares of common stock on March 10, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

  • On March 10, 2025, Faraz Ali, CEO of Tenaya Therapeutics, Inc., sold shares of the company's common stock.
  • The sales were executed in two separate transactions to cover tax withholding obligations associated with the vesting of restricted stock units.
  • In the first transaction, 5,794 shares were sold at a weighted average price of $0.5384.
  • In the second transaction, 3,947 shares were sold, also at a weighted average price of $0.5384.
  • Following these transactions, Ali directly owns 320,514 shares of Tenaya Therapeutics, Inc., which includes shares to be issued upon vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (selling shares to cover taxes) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Sales of shares by company executives are a common occurrence, often related to tax obligations or diversification of personal holdings. The impact on the stock price depends on the size of the sale relative to the overall trading volume and investor sentiment.

Comparison to Industry Standards

  • Executive stock sales are a routine part of compensation packages in publicly traded companies.
  • Similar sales are often seen at companies like Amgen, Gilead, and Biogen, where executives periodically sell shares acquired through stock options or restricted stock units to manage their personal finances and tax liabilities.
  • The scale of these transactions is generally considered normal unless they are unusually large or coincide with other significant company events.

Stakeholder Impact

  • The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context.

Key Dates

DateDescription
February 15, 2023Date of restricted stock units awarded, related to the first sale.
February 23, 2024Date of restricted stock units awarded, related to the second sale.
March 10, 2025Date of the share sales.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.